About 13 million young adults (ages 20-39 years) have high cholesterol and about six million have high blood pressure. Recent treatment guidelines have discouraged treatment of high blood pressure or high cholesterol in young adults. This is particularly true of cholesterol treatment guidelines, which are based on short-term (ten year) risk for cardiovascular disease. However, evidence is accumulating that high blood pressure or cholesterol in the young adult years is a strong predictor of later life cardiovascular disease, even after accounting for later life risk factors levels. For this project,we propose to build on this evidence by incorporating life course, age-related risk factor trajectorie and impact of young adult risk factor exposures into a microsimulation model of cardiovascular disease risk in young adults. We have assembled a team of experts in cardiovascular disease epidemiology, biostatistics, health economic evaluation, and computer simulation modeling in order to evaluate the incremental value of treating and controlling high blood pressure or cholesterol in U.S. young adults.
We aim to use this expertise and these methods in order to: ? Estimate the potential health benefits (life years gained) of early high blood pressure and cholesterol treatment and control during young adulthood, accounting for avoided cumulative atherosclerotic damage from early life exposures to these risk factors, and ? Project the potentil health benefits of early blood pressure and cholesterol treatment and control in young adults with pre-diabetes from 2015 to 2050. We hypothesize that treatment and control of high blood pressure and cholesterol before age 40 years would yield superior lifetime gains in quality-adjusted life years compared with controlling BP and cholesterol according to 10-year risk after age 40 years. However, we anticipate that these benefits will be very sensitive to adverse event rates and any potential quality of life decrement associated with years of adhering to healthful lifestyle choices or taking preventive medications on a daily basis. Relevance: The results of this study may change the way patients, health care providers, payers, and clinical guideline makers perceive CVD risk and the potential for early primary prevention in young adults, and may eventually contribute towards improved lifetime cardiovascular health in U.S. adults. The results have the potential to influence modifications to clinical practice guidelines and encourage worksite-based and other prevention programs targeted at young adult cardiovascular health promotion.

Public Health Relevance

About 13 million young adults (ages 20-39 years) have high cholesterol and about six million have high blood pressure, but recent treatment guidelines discourage treating these cardiovascular risk factors in young adults. Accumulating evidence suggests that high blood pressure or cholesterol in the young adult years is a strong and independent risk factor for later life cardiovascular disease. In this study, we will build on this evidence and use computer simulation in order to assess the potential health benefits from controlling high blood pressure and cholesterol in young adults now and in future years.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL107475-06
Application #
9493519
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Einhorn, Paula T
Project Start
2011-08-19
Project End
2019-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
6
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Zhang, Yiyi; Moran, Andrew E (2017) Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension Among Young Adults in the United States, 1999 to 2014. Hypertension 70:736-742
Vasudeva, Eshan; Moise, Nathalie; Huang, Chen et al. (2016) Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study. Am J Hypertens 29:1195-205
Moise, Nathalie; Huang, Chen; Rodgers, Anthony et al. (2016) Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model. Hypertension 68:88-96
Pletcher, Mark J; Vittinghoff, Eric; Thanataveerat, Anusorn et al. (2016) Young Adult Exposure to Cardiovascular Risk Factors and Risk of Events Later in Life: The Framingham Offspring Study. PLoS One 11:e0154288
Odden, Michelle C; Moran, Andrew E; Coxson, Pamela G et al. (2016) Gait Speed as a Guide for Blood Pressure Targets in Older Adults: A Modeling Study. J Am Geriatr Soc 64:1015-23
Gu, Dongfeng; He, Jiang; Coxson, Pamela G et al. (2015) The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study. PLoS Med 12:e1001860
Moran, Andrew E; Odden, Michelle C; Thanataveerat, Anusorn et al. (2015) Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med 372:447-55
Odden, Michelle C; Coxson, Pamela G; Moran, Andrew et al. (2011) The impact of the aging population on coronary heart disease in the United States. Am J Med 124:827-33.e5